These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 2459510

  • 1. 5-HT2-receptor antagonists: alpha 1- vs. 5-HT2-receptor blocking properties in blood vessels.
    Cohen ML, Schenck KW, Kurz KD.
    J Cardiovasc Pharmacol; 1988; 11 Suppl 1():S25-9. PubMed ID: 2459510
    [Abstract] [Full Text] [Related]

  • 2. LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat.
    Cohen ML, Fuller RW, Kurz KD.
    J Pharmacol Exp Ther; 1983 Nov; 227(2):327-32. PubMed ID: 6313898
    [Abstract] [Full Text] [Related]

  • 3. The alpha-adrenergic receptor blocking effect of ketanserin and the interaction between alpha-adrenergic and S2-serotonergic receptor blockade.
    van der Starre PJ, Reneman RS.
    J Cardiovasc Pharmacol; 1988 Nov; 11 Suppl 1():S54-61. PubMed ID: 2459516
    [Abstract] [Full Text] [Related]

  • 4. Antihypertensive effects of ketanserin and ritanserin in the spontaneously hypertensive rat.
    Persson B, Gradin K, Pettersson A, Hedner T.
    J Cardiovasc Pharmacol; 1988 Nov; 11 Suppl 1():S22-4. PubMed ID: 2459509
    [Abstract] [Full Text] [Related]

  • 5. Effects of antagonists of 5-hydroxytryptamine on blood pressure in the anesthetised spontaneously hypertensive rat.
    Docherty JR, Warnock P.
    J Cardiovasc Pharmacol; 1987 Nov; 10 Suppl 3():S59-61. PubMed ID: 2446073
    [Abstract] [Full Text] [Related]

  • 6. Serotonin-induced contraction in porcine coronary artery: use of ergolines to support vascular 5-hydroxytryptamine2-receptor heterogeneity.
    Cushing DJ, Cohen ML.
    J Pharmacol Exp Ther; 1993 Jan; 264(1):193-200. PubMed ID: 8423526
    [Abstract] [Full Text] [Related]

  • 7. Comparison between ketanserin and LY 53857 on vascular and cardiac 5-HT2 and alpha 1-adrenergic receptors in the pithed rat.
    Dabiré H, Chaouche-Teyara K, Cherqui C, Fournier B, Schmitt H.
    Arch Int Pharmacodyn Ther; 1990 Jan; 306():57-64. PubMed ID: 1981667
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the serotonin receptors that mediate smooth muscle contraction in canine and porcine coronary artery.
    Cushing DJ, Cohen ML.
    J Pharmacol Exp Ther; 1992 Jun; 261(3):856-62. PubMed ID: 1602389
    [Abstract] [Full Text] [Related]

  • 9. An investigation of the effects of intravenous injection of the 5-hydroxytryptamine 2 receptor antagonists ketanserin and LY 53857 on blood pressure in anesthetized spontaneously hypertensive rats.
    Docherty JR.
    J Pharmacol Exp Ther; 1989 Feb; 248(2):736-40. PubMed ID: 2537414
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological activity of the isomers of LY53857, potent and selective 5-HT2 receptor antagonists.
    Cohen ML, Kurz KD, Mason NR, Fuller RW, Marzoni GP, Garbrecht WL.
    J Pharmacol Exp Ther; 1985 Nov; 235(2):319-23. PubMed ID: 4057073
    [Abstract] [Full Text] [Related]

  • 11. Preclinical pharmacology of a new serotonergic receptor antagonist, LY281067.
    Cohen ML, Fuller RW, Kurz KD, Parli CJ, Mason NR, Meyers DB, Smallwood JK, Toomey RE.
    J Pharmacol Exp Ther; 1988 Jan; 244(1):106-12. PubMed ID: 3335993
    [Abstract] [Full Text] [Related]

  • 12. Evidence for two populations of 5-hydroxytryptamine receptors in dog basilar artery.
    Frenken M.
    J Pharmacol Exp Ther; 1989 Jul; 250(1):379-87. PubMed ID: 2545865
    [Abstract] [Full Text] [Related]

  • 13. Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle.
    Cohen ML, Schenck KW, Colbert W, Wittenauer L.
    J Pharmacol Exp Ther; 1985 Mar; 232(3):770-4. PubMed ID: 3973826
    [Abstract] [Full Text] [Related]

  • 14. Modulation by 5-HT1A receptors of the 5-HT2 receptor-mediated tachykinin-induced contraction of the rat trachea in vitro.
    Germonpré PR, Joos GF, Pauwels RA.
    Br J Pharmacol; 1998 Apr; 123(8):1571-8. PubMed ID: 9605563
    [Abstract] [Full Text] [Related]

  • 15. LY215840, a potent 5-hydroxytryptamine (5-HT)2 receptor antagonist, blocks vascular and platelet 5-HT2 receptors and delays occlusion in a rabbit model of thrombosis.
    Cohen ML, Robertson DW, Bloomquist WE, Wilson HC.
    J Pharmacol Exp Ther; 1992 Apr; 261(1):202-8. PubMed ID: 1560366
    [Abstract] [Full Text] [Related]

  • 16. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
    Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM.
    Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
    [Abstract] [Full Text] [Related]

  • 17. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM, Van Nueten JM, Symoens J, Janssen PA.
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [Abstract] [Full Text] [Related]

  • 18. Tryptaminergic receptors in the bovine pulmonary vasculature: effects of ketanserin.
    Ogunbiyi PO, Eyre P.
    Res Commun Chem Pathol Pharmacol; 1984 Apr; 44(1):31-55. PubMed ID: 6328601
    [Abstract] [Full Text] [Related]

  • 19. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
    Van Nueten JM, Janssen PA, Van Beek J, Xhonneux R, Verbeuren TJ, Vanhoutte PM.
    J Pharmacol Exp Ther; 1981 Jul; 218(1):217-30. PubMed ID: 6113280
    [Abstract] [Full Text] [Related]

  • 20. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J, Stott DJ, Robertson JI, Ball SG.
    J Cardiovasc Pharmacol; 1987 Jul; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.